Deborah Birx - 10 Jul 2026 Form 4 Insider Report for Armata Pharmaceuticals, Inc. (ARMP)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ARMP
Reported as of: 10 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jul 2026, 16:18:54 UTC
Prior SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Deborah Birx

Key filing fact

Deborah Birx filed Form 4 for Armata Pharmaceuticals, Inc. (ARMP) on 14 Jul 2026.

Key facts

This page summarizes Deborah Birx's Form 4 filing for Armata Pharmaceuticals, Inc. (ARMP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Jul 2026, 16:18.

Change

Previous filing in this sequence was filed on 17 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001849673 Primary reporting owner

Birx Deborah

Relationship: Chief Executive Officer, Director
Address: 5005 MCCONNELL AVENUE, LOS ANGELES
Signature: /s/ Deborah Birx
Signature date: 14 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARMP transaction

Common Stock

Tax liability

Transaction value
Shares: -14,041
Change %: -6.6%
Price: $4.26^*
Shares after: 198,417
Date: 10 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.